[Unrelated or sibling donor allogeneic bone marrow transplantation for myelodysplastic syndrome].
OBJECTIVE
To study on allogeneic bone marrow transplantation (BMT) with unrelated donor or sibling donor for myelodysplastic syndrome-refractory anemia and myelodysplastic syndrome-refractory anemia with excess blasts in transformation patients.


METHODS
Two male patients received chemotherapy regimen of busulfan-cyclophosphamide before allogeneic BMT. Mycophenolate mofetil combined with cyclosporin A and methotrexate was used for prevention of acute graft-versus-host disease after transplantation. Low dose heparin and lipo prostaglandin E1 were used in prophylactic regimen for hepatic veno-occlusive disease.


RESULTS
Neutrophil count began to be higher than 0.5 x 10(9)/L on 21st and 17th days after BMT in the two patients. Disease-free survival in the two patients was 10 months and 3.5 months respectively.


CONCLUSIONS
Allogeneic bone marrow transplantation with unrelated or sibling donor is an effective therapy for patients with MDS.
Huang
H
H
Department of Hematology, First Affiliated Hospital, Zhejiang University, Hangzhou 310003, China.
Lin
M
M
Meng
H
H
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D012801:Sibling Relations; D014019:Tissue Donors